海思科(002653.SZ):海思科控股集團擬以7422.43萬美元收購美國海思科和新加坡創新藥公司各100%股權
格隆匯3月3日丨海思科(002653.SZ)公佈,公司全資孫公司Haisco Holdings PTE.LTD. (“海思科控股”)持有Haisco Pharmaceutical Holdings Group Limited (“海思科藥業控股集團”)80%股權。
海思科藥業控股集團持有Haisco-USA Pharmaceuticals,Inc. (“美國海思科”)100%股權、持有Haisco Innovative Pharmaceutical PTE. LTD. (“新加坡創新藥公司”)100%股權。
基於公司發展規劃,公司三級全資子公司Haisco Holdings Group Limited (“海思科控股集團”)擬以自有資金共計7422.43萬美元收購海思科藥業控股集團持有的美國海思科100%股權和新加坡創新藥公司100%股權,其中:美國海思科股權受讓價款為1882.04萬美元,新加坡創新藥公司股權受讓價款為5540.39萬美元。
美國海思科目前主要負責開展HSK3486乳狀注射液鎮靜/麻醉藥物Ⅲ期臨牀試驗,目前未有營業收入,但為保證其正常運轉需支付相關費用,故淨利潤為負。此次收購該公司100%股權是為進一步整合資源,提高管理決策效率,推進創新藥在海外的臨牀研究,加快產品的國際化進程。
新加坡創新藥公司持有HSK3486乳狀注射液鎮靜/麻醉藥物在中國內地以外市場(含港澳台)的專有技術所有權,目前未有營業收入,但為保證其正常運轉需支付相關費用,故淨利潤為負。此次收購該公司100%股權是為進一步整合資源,提高管理決策效率,推進創新藥在海外的臨牀研究,加快產品的國際化進程。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.